Compare Dulaglutide (evidence A) and Liraglutide (evidence A) on mechanism, clinical status, safety, and dosing.
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved in September 2014 for type 2 diabetes. It is a…
Liraglutide is an FDA-approved GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1. Developed by Novo Nordisk, it is…
Full profiles: Dulaglutide, Liraglutide.